Agios Pharmaceuticals, Inc.

NasdaqGS:AGIO Stock Report

Market Cap: US$2.4b

Agios Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:AGIO Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
08 Nov 24SellUS$43,301T. WashburnIndividual772US$56.09
03 Jun 24SellUS$60,459T. WashburnIndividual1,362US$44.39
07 Mar 24SellUS$40,632Kaye Foster-CheekIndividual1,285US$31.62
06 Mar 24SellUS$150,899Kaye Foster-CheekIndividual4,715US$32.21
05 Mar 24SellUS$60,738T. WashburnIndividual1,913US$31.75
20 Feb 24SellUS$13,422T. WashburnIndividual504US$26.63

Insider Trading Volume

Insider Buying: AGIO insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of AGIO?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders847,1921.43%
Hedge Funds5,660,8669.53%
Institutions52,923,59489%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2%.

Top Shareholders

Top 25 shareholders own 82.23% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.93%
Farallon Capital Management, L.L.C.
5,660,866US$237.5m0.11%1.37%
9.72%
The Vanguard Group, Inc.
5,545,982US$232.7m0.9%no data
8.81%
BlackRock, Inc.
5,021,767US$210.7m3.35%no data
6.55%
Bellevue Asset Management AG
3,735,915US$156.8m-3.7%1.75%
4.97%
T. Rowe Price Group, Inc.
2,832,512US$118.9m1.99%0.01%
4.09%
State Street Global Advisors, Inc.
2,331,433US$97.8m10.2%no data
3.87%
Armistice Capital LLC
2,207,070US$92.6m6.15%2.18%
3.83%
Erste Asset Management GmbH
2,184,900US$91.7m-3.1%0.66%
2.96%
Macquarie Investment Management Business Trust
1,690,801US$70.9m-2.25%0.07%
2.91%
JP Morgan Asset Management
1,659,181US$69.6m-0.78%0.01%
2.74%
Dimensional Fund Advisors LP
1,562,183US$65.5m-28.9%0.01%
2.38%
Geode Capital Management, LLC
1,357,531US$57.0m0.45%no data
2.22%
Marshall Wace LLP
1,263,285US$53.0m11.4%0.07%
2.09%
BVF Partners L.P.
1,190,107US$49.9m0%1.47%
1.83%
Frazier Life Sciences Management, LP
1,044,154US$43.8m19.8%1.63%
1.76%
Polar Capital Holdings Plc
1,002,036US$42.0m0%0.14%
1.59%
BNPP Asset Management Holding
907,044US$38.1m-0.45%0.05%
1.55%
ArrowMark Colorado Holdings, LLC
882,731US$37.0m-13.4%0.43%
1.5%
Fisher Asset Management, LLC
855,328US$35.9m20.5%0.01%
1.33%
Vestal Point Capital, LP
760,000US$31.9m0%2.35%
1.23%
Rock Springs Capital Management LP
699,389US$29.3m-33%0.92%
1.17%
Deutsche Asset & Wealth Management
669,615US$28.1m1.11%0.01%
1.11%
GW&K Investment Management, LLC
630,946US$26.5m6.03%0.19%
1.07%
Loomis Sayles & Company, L.P.
612,366US$25.7m36.4%0.03%
1.03%
Northern Trust Global Investments
590,108US$24.8m0.66%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 12:35
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Agios Pharmaceuticals, Inc. is covered by 32 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
George FarmerBMO Capital Markets Equity Research
Alec StranahanBofA Global Research